Piper Jaffray analyst Matt O'Brien raised his price target for Boston Scientific to $42 from $40 following this morning's "solid" Q4 results. The "strong" revenue outlook trumps the slightly below consensus earnings guidance, O'Brien tells investors in a post-earnings research note. The outlook calls for organic constant currency sales growth in the range of 7%-8.5%, which is ahead of Street expectations and toward the high end of management's longer-term outlook, says the analyst. On the bottom line, management is calling for earnings per share in the range of $1.53-$1.58, which only touches the consensus at the high end, he adds. O'Brien was "initially concerned" by the earnings outlook, but he now believes investors are comfortable with the investments management continues to make in the business. He remains constructive on Boston Scientific and reiterates an Overweight rating.